CompuGroup Medical SE

  • WKN: 543730
  • ISIN: DE0005437305
  • Land: Deutschland

Nachricht vom 11.02.2019 | 10:48

CompuGroup Medical SE: Release of a capital market information

CompuGroup Medical SE / Share Buyback

11.02.2019 / 10:48
Dissemination of a Post-admission Duties announcement transmitted by DGAP -
a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


CompuGroup Medical SE: Disclosure pursuant to Art. 5 Para. 1 lit. b) and Para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Para. 2 and Para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 8th Interim Announcement CompuGroup Medical SE / Share Buyback Koblenz, February 11 2019 CompuGroup Medical SE: Disclosure pursuant to Art. 5 Para. 1 lit. b) and Para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 Para. 2 and Para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 - 8th Interim Announcement In the period from February 4, 2019, up to and including February 8, 2019, CompuGroup Medical SE has bought back a total of 35,417 shares of CompuGroup Medical SE within the framework of the share buyback program. In the announcement of December 14, 2018, pursuant to Art. 2 para. 1 of the Commission Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 (MAR) it was communicated that the repurchase of treasury shares would commence on December 17, 2018. The overall volume of the shares bought back daily in the period from February 4, 2019, up to and including February 8, 2019, and the daily volume-weighted average stock market prices of the shares are as follows:

Date                   Overall volume of      Volume-weighted average
                       shares bought back     stock market price
                       (number)               (EUR, excluding ancillary
                                              costs of purchase, rounded
                                              to four places according to
                                              commercial practice)
February 4, 2019       2,534                  47.5930
February 5, 2019       7,021                  48.2803
February 6, 2019       6,400                  48.7610
February 7, 2019       10,812                 48.8011
February 8, 2019       8,650                  48.6587
In total:              35,417                 48,5694


The total number of shares which have been bought back so far by CompuGroup Medical SE since December 17, 2018, up to and including February 8, 2019, within the framework of the share buyback program thus amounts to 223,989 no-par value shares. Further information pursuant to Art. 5 para. 1 lit. b) and para. 3 of the Regulation (EU) No 596/2014 (MAR) in conjunction with Art. 2 para. 2 and para. 3 of the Commission Delegated Regulation (EU) No 2016/1052 is available online under https://www.cgm.com/sbb. The purchase of the shares of CompuGroup Medical SE was carried out by a bank assigned by CompuGroup Medical SE and exclusively via the Frankfurt Stock Exchange (Xetra trading). Koblenz, February 11, 2019 The Management Board CompuGroup Medical SE Investor Relations Maria Trost 21 56070 Koblenz, Germany T: 49 (0) 261 8000-6200 F: 49 (0) 261 8000-3200
11.02.2019 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Language: English Company: CompuGroup Medical SE Maria Trost 21 56070 Koblenz Germany Internet: www.cgm.com End of News DGAP News Service

GBC-Fokusbox

Syzygy AG: EBIT-Prognose überfüllt, weiteres Wachstum in Sicht

Mit einer erneut außerordentlich guten Entwicklung der in Deutschland ansässigen Tochtergesellschaften war der SYZYGY-Konzern in der Lage, die Umsatzbasis auf 65,82 Mio. EUR (VJ: 60,67 Mio. EUR) auszubauen. Das Zuwachs von 8,5 % liegt leicht unter der ursprünglichen Unternehmens-Guidance eines zweistelligen Umsatzwachstums. Die Prognose einer EBIT-Marge im oberen einstelligen Bereich wurde aber voll erfüllt. Auf Basis der erreichten Neukundengewinne prognostiziert das Unternehmensmanagement für 2019 ein Umsatzwachstum in einem hohen einstelligen Prozentbereich. Das EBIT sollte um rund 10 % und damit überproportional ansteigen. Unsere Analysten sind weiter positiv für das Unternehmen mit einem Kursziel von 12,15 EUR je Aktie.

Aktuelle Research-Studie

SAF-HOLLAND S.A.

Original-Research: SAF-Holland S.A. (von Montega AG): Kaufen

18. April 2019